Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Myriad is a biopharmaceutical company focused on developing therapeutic and molecular diagnostic products. Its operations are divided into three segments: Predictive Medicine (commercial testing), Research (gene discovery), and Drug Development (therapeutics). The company has not yet attained profitability and relies on cash reserves and potential financing to fund operations.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2005 | 9 Months Ended Mar 31, 2005 |
|---|---|---|
| Total Revenues | $19,961 | $56,310 |
| Predictive Medicine Revenue | $18,386 | $50,350 |
| Research Revenue | $1,575 | $5,960 |
| Net Loss | $(9,986) | $(30,026) |
| Loss Per Share (Basic & Diluted) | $(0.32) | $(0.98) |
| Cash and Cash Equivalents | $48,393 | $48,393 (Balance Sheet) |
| Total Marketable Securities | $66,890 | $66,890 (Balance Sheet) |
| Accumulated Deficit | $(169,297) | $(169,297) (Balance Sheet) |
| Net Cash Used in Operating Activities | N/A | $(24,805) |
Margins: Predictive medicine gross profit margin was 71% for both the three and nine-month periods ended March 31, 2005, an increase from 68% and 67% respectively in the prior year periods.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 45% for the three months and 35% for the nine months compared to the prior year periods. This was driven primarily by a 57% (quarterly) and 67% (year-to-date) increase in Predictive Medicine revenue due to wider medical acceptance and increased sales efforts.
- Research Revenue Decline: Research revenue decreased 23% (quarterly) and 48% (year-to-date) due to the completion of specific research collaborations and a strategic shift toward internal drug development.
- Expense Increases:
- R&D Expenses: Increased 25% (quarterly) and 12% (year-to-date) due to ongoing clinical trials and drug discovery programs.
- Selling, General & Administrative (SG&A): Increased 11% (quarterly) and 23% (year-to-date), largely attributable to commissions and marketing expenses supporting the growth in predictive medicine sales.
- Liquidity: Cash, cash equivalents, and marketable investment securities decreased by $26.6 million (19%) from June 30, 2004, to March 31, 2005, primarily due to expenditures for clinical trials and internal R&D.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Profitability: The company expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and new product launches.
- Clinical Trials:
- Flurizan (Alzheimer's): Preliminary Phase 2 results announced May 2, 2005, did not achieve statistical significance in mild-to-moderate patients but showed a positive trend in mild patients. Phase 3 trial modifications are under consideration.
- MPC-6827 (Cancer): Phase 1 studies initiated for advanced solid tumors and metastatic brain cancer.
- MPC-2130 (Cancer): Phase 1 study ongoing for advanced metastatic tumors and blood cancers.
- Capital Resources: Management believes existing resources are adequate for at least the next two years. A shelf registration statement for up to $300 million in securities was declared effective by the SEC on April 20, 2005.
Risks and Contingencies
- Accounting Changes: The company accelerated the vesting of approximately 3.5 million stock options in April 2005 to avoid significant charges under the new FASB Statement No. 123R (effective July 1, 2005). This resulted in a one-time expense of approximately $231,000.
- Market Risk: Investments are subject to interest rate risk, though a hypothetical 10% rate increase was deemed to have an insignificant impact on fair market value.
- Legal: No material legal proceedings were reported as of the filing date.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $24.8 million operating cash burn over the nine-month period against the $115.3 million total liquid assets.
- Flurizan Phase 3 Strategy: Monitor upcoming announcements regarding modifications to the Phase 3 Alzheimer's trial following the mixed Phase 2 results.
- Revenue Concentration: Note that 92% of total revenue (quarterly) comes from Predictive Medicine; verify the stability of this segment against potential market saturation or reimbursement changes.
- Stock-Based Compensation: Review the pro forma impact of FASB 123R adoption, which would have increased the nine-month net loss to approximately $49.1 million under fair value accounting.
- Research Revenue Volatility: Assess the risk of further declines in research revenue as the company transitions away from external collaborations to internal development.